New pill shows promise against Hard-to-Treat cancers
NCT ID NCT05585320
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests an experimental oral drug called IMM-1-104, which blocks certain cancer-driving proteins. It is given alone or with standard chemotherapy to people with advanced solid tumors that have RAS mutations, including pancreatic, melanoma, and lung cancers. The trial aims to find the safest dose and see if the drug can shrink tumors. About 209 adults are participating across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IMM-1-104 (an oral MEK1/2 inhibitor), given alone or with gemcitabine and nab-paclitaxel
What this could lead to
If successful, this could provide a new oral treatment option for people with certain advanced cancers that have RAS mutations, potentially shrinking tumors or slowing their growth.
What could go wrong
This is an early-phase trial (Phase 1/2a) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects from the drug or chemotherapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope
Duarte, California, 91010, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Cancer Institute
Durham, North Carolina, 27710, United States
-
Florida Cancer Specialists and Research Institute
Lake Mary, Florida, 32746, United States
-
Hematology Oncology Associates of Central New York
East Syracuse, New York, 13057, United States
-
Levine Cancer Center
Charlotte, North Carolina, 28204, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Mayo Clinic
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 27203, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
Sarcoma Oncology Center
Santa Monica, California, 90403, United States
-
University of California San Diego
San Diego, California, 92037, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Wisconsin Clinical Science Center
Madison, Wisconsin, 53792, United States
-
Weill Cornell Medicine
New York, New York, 10021, United States